Cited by 258IL-33, ST2, and ILC PathwaysAsthma and respiratory diseasesDermatology and Skin Diseases

IL-33 promotes airway remodeling in pediatric patients with severe steroid-resistant asthma

Open access
Saglani, Sejal, Lui, Stephen, Ullmann, Nicola, Campbell, Gaynor A., Sherburn, Rebekah T., Mathie, Sara A., Denney, Laura, Bossley, Cara J. +4 more·2013·Journal of Allergy and Clinical Immunology

Abstract

Background TH2 cytokines are not responsible for the ongoing symptoms and pathology in children with severe therapy-resistant asthma (STRA). IL-33 induces airway hyperresponsiveness, but its role in airway remodeling and steroid resistance is unknown. Objective We sought to investigate the relationship between IL-33 and airway remodeling in pediatric patients with STRA. Methods IL-33 levels were quantified in neonatal mice given inhaled house dust mite (HDM), and the effect of blocking IL-13 on remodeling and IL-33 levels was assessed. HDM-induced allergic airways disease (AAD) in neonatal ST2(-/-) mice lacking the IL-33 receptor was assessed, together with collagen production after IL-33 administration. The effect of steroid therapy on IL-33 levels in patients with neonatal AAD was explored. IL-33 expression was quantified in endobronchial biopsy (EB) specimens from children with STRA and related to remodeling, and collagen production by airway fibroblasts from pediatric patients stimulated with IL-33 and budesonide was quantified. Results Blocking IL-13 after AAD was established in neonatal mice and did not reduce remodeling or IL-33 levels; airway hyperresponsiveness was only partially reduced. IL-33 promoted collagen synthesis both from asthmatic fibroblasts from pediatric patients and after intranasal administration in mice. Increased cellular expression of IL-33, but not IL-13, was associated with increased reticular basement membrane thickness in EB specimens from children with STRA, whereas remodeling was absent in HDM-exposed ST2(-/-) mice. IL-33 levels were maintained, whereas IL-13 levels were abrogated by steroid treatment in neonatal HDM-exposed mice and in EB specimens from children with STRA. Conclusion IL-33 is a relatively steroid-resistant mediator that promotes airway remodeling in patients with STRA and is an important therapeutic target.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.jaci.2013.04.012

Cites

37 of 37 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Saglani, S., Lui, S., Ullmann, N., Campbell, G. A., Sherburn, R. T., Mathie, S. A., Denney, L., Bossley, C. J., Oates, T., Walker, S. A., Bush, A., & Lloyd, C. M.
Affiliations
  • Royal Brompton Hospital (GB)
  • Imperial College London (GB)
Corresponding author
Lloyd, Clare M.
Venue
Journal of Allergy and Clinical Immunology
Publisher
Elsevier BV
Published
2013-09
Volume
132
Issue
3
Pages
676-685.e13
ISSN
0091-6749 (ISSN-L)
OpenAlex
W2030003617
Cited by
258
References
37
Citations by year
2026: 6 · 2025: 12 · 2024: 12 · 2023: 11 · 2022: 14 · 2021: 27 · 2020: 22 · 2019: 34 · 2018: 19 · 2017: 30 · 2016: 20 · 2015: 23 · 2014: 25 · 2013: 2 · 2012: 1
FWCI
10.20
Type
journal article
Language
en
Open access
Locations
  • Journal of Allergy and Clinical Immunology (publishedVersion)
  • PubMed (publishedVersion)
  • PubMed Central (acceptedVersion)
Funders
  • Wellcome Trust (087618)
  • National Institute for Health and Care Research (NF-SI-0510-10192)
  • Medical Research Council (MR/J010529/1)
Topics
  • Life Sciences › Immunology and Microbiology › Immunology › IL-33, ST2, and ILC Pathways
  • Health Sciences › Medicine › Physiology › Asthma and respiratory diseases
  • Health Sciences › Medicine › Dermatology › Dermatology and Skin Diseases
Keywords
IL-33, airway remodeling, steroid-resistant asthma, childhood asthma, IL-13, allergic airway disease, house dust mites, airway hyperresponsiveness, collagen synthesis, airway fibroblasts, budesonide, bronchial biopsy
MeSH terms
Interleukin-33, Adolescent, Animals, Animals, Newborn, Anti-Inflammatory Agents, Asthma, Child, Collagen, Drug Resistance, Female, Glucocorticoids, Humans, Interleukins, Male, Mice, Inbred BALB C, Bronchial Hyperreactivity, Mice, Knockout, Interleukin-13, Budesonide, Pyroglyphidae, Mice, Airway Remodeling

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review